# Managed Access Programs for TQJ230, Pelacarsen

> **NCT07000695** · — · AVAILABLE · sponsor: **Novartis Pharmaceuticals**

## Conditions studied

- Atherosclerotic Cardiovascular Disease, ASCVD

## Interventions

- **DRUG:** Pelacarsen

## Key facts

- **NCT ID:** NCT07000695
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2025-06-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07000695

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07000695, "Managed Access Programs for TQJ230, Pelacarsen". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT07000695. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*